retatrutide latest trial results Weight Loss Results:Trial Data and FDA Status Percent of participants achieving liver

A study of more than 110,000 women found those who took popular GLP-1 drugs prescribed for obesity or diabetes had a lower risk of breast cancer.

Truveta Research tracks GLP-1 RA prescribing through March 2026, showing accelerated anti-obesity use and a sharp rise in first-time semaglutide prescribing.

The GlucoZen Blend supports a balanced metabolic rate and steady energy, helping you stay active and focused

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).

The research was presented at theAmerican College of Cardiologys Annual Scientific Session

This review discusses the clinical and physiological changes, and in particular, the mechanisms behind weight loss and glycaemic improvements, observed following the gastric bypass, sleeve gastrectomy and gastric banding bariatric procedures